Merus NV
🇳🇱Netherlands
- Country
- 🇳🇱Netherlands
- Ownership
- Public
- Established
- 2003-01-01
- Employees
- 229
- Market Cap
- $3.6B
- Website
- http://www.merus.nl
5-Year Analysis of Phase III HIMALAYA Confirms Survival Benefit of STRIDE in ...
The HIMALAYA study's 5-year survival analysis shows 19.6% survival with STRIDE (durvalumab plus tremelimumab) vs 9.4% with sorafenib in unresectable hepatocellular carcinoma, with no new safety concerns.
© Copyright 2024. All Rights Reserved by MedPath